GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

K Pharma 4896.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

657

+6.83%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

—

FY2021FY2025

Net income

−¥993.2m

FY2021FY2025

Free cash flow

−¥929.2m

FY2021FY2025

Shareholders' equity

¥1.27bn

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Revenue——¥1.00bn——
Gross profit——¥910.0m—−¥6.8m
Research and development—¥451.6m¥255.4m¥164.0m¥134.5m
Operating income−¥916.1m−¥836.3m¥366.1m−¥353.8m−¥219.5m
Net income−¥993.2m−¥846.5m¥260.3m−¥392.4m−¥228.7m
Diluted earnings per share-85.58-72.9427.90-33.76-19.68

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets¥2.94bn¥2.35bn¥3.31bn¥1.37bn¥205.8m
Cash and short-term investments¥2.79bn¥2.27bn¥3.27bn¥1.34bn¥188.8m
Total liabilities¥1.67bn¥94.8m¥209.1m¥38.3m¥26.9m
Debt¥1.50bn————
Shareholders' equity¥1.27bn¥2.26bn¥3.10bn¥1.34bn¥178.9m
Shares outstanding12m12m9m12m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−¥918.0m−¥983.7m¥454.4m−¥363.5m−¥196.3m
Capital spending−¥11.2m−¥14.5m−¥9.8m−¥30.0m—
Free cash flow−¥929.2m−¥998.2m¥444.6m−¥393.4m−¥196.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−¥233.8m−¥237.3m−¥247.6m−¥231.1m−¥238.7m−¥198.7m−¥215.4m−¥197.5m
Net income−¥242.1m−¥250.6m−¥311.3m−¥237.2m−¥245.5m−¥199.1m−¥222.1m−¥197.8m
Diluted earnings per share-20.83-21.56-26.82-20.44-21.16-17.16-19.14-17.05
Total assets¥2.57bn¥2.82bn¥2.94bn¥1.68bn¥1.94bn¥2.15bn¥2.35bn¥2.60bn
Cash and short-term investments¥2.36bn¥2.71bn¥2.79bn¥1.50bn¥1.84bn¥2.08bn¥2.27bn¥2.52bn
Debt¥1.64bn¥50.0m¥1.50bn—————
Shareholders' equity¥773.6m¥1.02bn¥1.27bn¥1.58bn¥1.81bn¥2.06bn¥2.26bn¥2.48bn

Financial ratios

Data as of 8 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin——91.0%——
Operating margin——36.6%——
Net margin——26.0%——
Return on equity-78.5%-37.5%8.4%-29.4%-127.9%
Return on assets-33.8%-36.0%7.9%-28.5%-111.2%
Free cash flow yield-10.5%-11.2%6.7%——
Earnings growth17.3%-425.1%-166.3%71.6%—
Current ratio28.41x37.00x18.54x40.70x8.76x
Debt to equity1.19x0.00x———
Equity ratio43.1%96.0%93.7%97.2%86.9%
Interest coverage-135.03x—30.89x——
R&D as a share of sales——25.5%——
Buybacks as a share of market value-0.0%-24.4%———

Growth per year

Compound annual rate

3 years5 years10 years
Operating income37.3%——
Net income36.3%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings-7.7-8.525.8
Price to sales——6.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.